Here's a summary of the provided company information, broken down into relevant sections:

##Platform and Product Development##
The company, identified by the ticker NGAI, launched its core AI module for the NeuraDiagnose Platform on April 7, 2020. This was followed by the beta release of the PredictCare AI Suite for oncology forecasting on September 2, 2021.

##Regulatory and Market Achievements##
A significant milestone was achieved on June 16, 2022, when the company received FDA breakthrough software designation. Demonstrating market traction, NGAI secured a large NHS Trust rollout win on November 14, 2023.

##Market Challenges and Resolution##
On March 27, 2024, a 'data bias' scandal emerged within the competitive market, prompting an internal audit. However, by August 19, 2024, the internal audit cleared integrity concerns, and patient safety filings were accelerated.

##Strategic Partnerships and Market Positioning##
The company announced a strategic joint venture with Medisafe Health and Borealis (C003) on February 10, 2025. Subsequently, on May 23, 2025, a contender pricing model was launched amidst sector value compression. The post-JV period, as of August 19, 2025, shows a stable close with improving revenue momentum.
